We have recently reported altered levels of protein kinase A and Rap1 in patients with bipolar disorder. The purpose of the current investigation was to assess the levels of these proteins in platelets from untreated euthymic and depressed patients with major unipolar depression. Platelets were collected from 45 drug-free unipolar patients (13 euthymic and 32 depressed) and 45 healthy subjects. The levels of protein kinase A and Rap1 were assessed by Western blot analysis, immunostaining and computer-assisted imaging. The immunolabeling of the regulatory subunit type II of protein kinase A and that of Rap1 was significantly lower in untreated depressed patients compared with untreated euthymic patients and healthy subjects. No significant differences were found in the immunolabeling of both the regulatory type I and the catalytic subunits of protein kinase A among groups. Levels of the regulatory subunit type II of protein kinase A and Rap1 are altered in platelets of unipolar depressive patients. These findings may provide new insight about the relationship between components of cAMP signaling and affective disorders. Molecular Psychiatry (2001) 6, 44-49.
Introduction
The cAMP signaling cascade is a transduction mechanism by which various extracellular signals regulate cellular functions. A noteworthy feature of this pathway is that almost all of the cellular effects of cAMP are mediated through the activation of protein kinase A (PKA). [1] [2] [3] The inactive PKA is a tetramer consisting of two catalytics (C) and a regulatory (R) subunits dimer. When cAMP rises within the cell, the enzymatic activation proceeds through a reaction where it binds the R subunits and the tetrameric complex subsequently dissociates into a R dimer and two free C subunits. Once released from the holoenzyme state, C moieties are able to phosphorylate substrate proteins such as receptors, ion channels, cytoskeleton proteins, phosphatase inhibitors and transcription factors among others. [1] [2] [3] During the last decade, a great number of preclinical studies have shown that the cAMP binding, the activity and the levels of PKA are altered after administration of antidepressants and mood stabilizers.
More recently, clinical investigations have shown dysfunctions in the cAMP-dependent phosphorylation system in postmortem brain and peripheral cells of patients with affective disorders. [7] [8] [9] [10] [11] [12] [13] [14] [15] In this context, we have reported that the cAMP-dependent phosphorylation and the levels of Rap1, a well recognized PKA substrate belonging to the Ras family of small guanosine triphosphate-binding proteins, 16 were shown to be significantly higher in platelets of untreated euthymic patients with bipolar disorder than in healthy subjects. [17] [18] [19] [20] The levels of Rap1 were also found higher in untreated depressed and manic patients with bipolar disorder than in controls. 20 Furthermore, the levels of the PKA C subunits in depressed and manic patients with bipolar disorder were significantly higher than in euthymic bipolar patients and healthy subjects, whereas no significant differences among groups were found in the R subunits. 20 Overall these findings suggest that disturbances of PKA and some of its substrates may be associated with affective disorders. However, it remains to be elucidated whether the levels of such components may also be altered in unipolar depression. Thus, the objective of the current study was to assess the levels of PKA and Rap1 in platelets from untreated euthymic or depressed patients with major depression and healthy subjects.
Materials and methods

Subjects
After providing written informed consent, 45 patients (18 male and 27 female; mean age 41.6 ± 10.2 years) and 45 age and sex-comparable healthy volunteers (18 male and 27 female; mean age 38.6 ± 9.6 years) were included in this study. All patients, recruited at the Mood Disorders Clinical and Research Unit, San Raffaele Hospital (Milan), met the full criteria for major depressive disorder according to DSM-IV. 21 Those with a history of important acute or chronic medical illness, or alcohol or psychotropic drug abuse were excluded. Lifetime diagnoses were assigned by trained psychiatrists and supervised by an independent senior psychiatrist on the basis of unstructured clinical interviews and medical records, according to DSM-IV criteria and following a best estimate procedure. Clinical information was collected directly from each patient and from at least one close relative as a coinformant. Medical health was documented by the medical history, physical examination, electrocardiography, blood and serum chemical analyses (including hepatic and renal profiles), and thyroid function tests.
The patients' group comprised: 32 inpatients with depressive episode (score Ͼ21 on the 21-item Hamilton Depression Rating Scale), 22 and 13 outpatients in euthymic condition (score Ͻ8 on the Hamilton Depression Rating Scale). Euthymic and depressed patients had been free of antidepressants for at least 6 months and of all medications for at least 3 months before blood specimens were drawn. None of the patients received antidepressants as maintenance therapy. Patients had been treated with antidepressants only in previous episodes occurring at least 12 months before the current episode.
The mean ± SD duration of the index depressive episode was 3.9 ± 1.4 weeks. The mean ± SD age of the 32 depressed patients was 41.1 ± 10.2 years; and of the 13 euthymic patients 42.3 ± 10.6 years. The ages at onset were 33.4 ± 10.8 years, and 35.9 ± 9.8 years, respectively. The mean ± SD number of previous episodes was 1.9 ± 1.4 in depressed patients, and 1.1 ± 0.7 in euthymic patients. The sex distribution (male:female) in the two groups was 10:22, and 8:5 respectively.
The comparison group included 45 consenting volunteers, who had no personal or familial history of mental disorders, alcoholism, or drug abuse and no active medical problems, as determined by clinical interview. To exclude the presence of a personal or familial history of mental disorders, the proband and, when possible, other members of the proband's family or social group were interviewed. The healthy subjects were free of all drug treatments for at least 3 months before the study and none was part of previous studies.
Platelets isolation and immunoblot analysis
A morning blood specimen (50 ml) was obtained from healthy volunteers and major depressive patients by Molecular Psychiatry venipuncture and placed in tubes containing sodium citrate as an anticoagulant. Platelets were isolated as previously described. 20 Pellets were then rinsed three times with cold Tris hydrochloride isotonic buffer and then frozen at −80°C until subsequent use. On the day of the assay, platelets were homogenized by sonication with 2 × 15-s pulses in cold Tris hydrochloride buffer (10 mmol l −1 ) containing, egtazic acid (1 mmol l
), aprotinin (50 U ml
) and phenylmethylsulfonyl fluoride (0.1 mmol l −1 ), pH 7.4. Platelets were prepared and then analyzed by personnel unaware of the diagnosis. Protein concentrations were determined in duplicate according to the method of Bradford. 23 The linearity of the platelet protein concentration for the Western Blotting experiments was ascertained by resolving selected quantities of proteins, between 2 and 25 g. The relationship between the total amount of proteins loaded into the gels and the integration of area × optical density was linear within 2-15 g protein range.
Whole platelet homogenates from each subject were solubilized in denaturing buffer and boiled for 2 min. Aliquots with equal amounts of proteins (5 g) were loaded on 12% polyacrylamide gels and subjected to one-dimensional electrophoresis (sodium-dodecyl sulfate polyacrylamide gel electrophoresis). Patients' specimens were always run in duplicate or triplicate on the same gel with those of their respective controls. Proteins, thus resolved in bands, were electrophoretically transferred onto Hybond polyvinylidene difluoride membrane (Amersham Int, Amersham, Bucks, UK) for 90 min at 100 V. Blots were then preincubated for 1 h in Tris buffered saline-Tween 20 buffer, pH 7.6 (Tris hydrochloride, 25 mmol l ; sodium chloride, 137 mmol l −1 ; and 0.1% Tween-20) containing 1% of bovine serum albumin (blocking buffer). All incubations were performed at room temperature. After a thorough washing with TBS-T, the blots were incubated in blocking buffer for 90 min with monoclonal antibodies against the R type I (RI) (Transduction Laboratories, Lexington, KY, USA; dilution 1:500), the R type II (RII) (Biomol, Plymouth Meeting, PA, USA; dilution 1:2000), and the catalytic (C) (Transduction Laboratories; dilution 1:500) subunits of PKA, Rap1 (Transduction Laboratories; dilution 1:2500), and actin (clone DC40, Sigma-Aldrich Corp, St Louis, MO, USA; dilution 1:3500). After being extensively washed with TBS-T the blots were incubated with the second antibody, horseradish peroxidase-linked antimouse (Sigma-Aldrich Corp; dilution 1:1000), in blocking buffer for 1 h. The labeled blots were then washed with TBS-T and immunoreactivity was detected with the Western blot detection system (Enhanced Chemiluminescent, Amersham International), followed by exposure to film. Quantitation of the immunoblots was performed by densitometric scanning of the autoradiograms using an image analysis system (National Institute of Health Image, version 1.47, Bethesda, MD, USA).
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An aliquot of pooled standard platelet proteins was run on one lane of every gel to minimize the inter-assay variation, as previously described. 20 The optical density units obtained from each subject were normalized against those from a pooled platelet standard.
Statistical analysis
Data were analyzed using a one-way analysis of variance (two-tailed) followed by Newman-Keuls post hoc comparison tests. Results are expressed as means ± SD. The level of significance was P Ͻ 0.05. Figure 1 illustrates representative immunoblots of PKA subunits, Rap1 and actin immunoreactivities in whole platelet proteins from untreated unipolar patients in euthymia, or depression and from healthy subjects.
Results
The monoclonal antibodies against the R (type I or type II) or the C subunits of PKA revealed the presence of major platelet protein bands migrating with apparent molecular masses of 49, 52 and 40 kDa, respectively. The anti-Rap1 antibody recognized a single band with an apparent molecular mass of 21 kDa, and the antiactin antibody a single band with an apparent molecular mass of 42 kDa. Quantitation of immunoblots was obtained through densitometric scanning of autoradiographs. Data were then normalized and analyzed as described in the Materials and methods section.
The analysis of variance revealed no significant difference in the levels of either the RI (F 2,87 = 2.36; P = 0.10) or the C (F 2,87 = 0.40; P = 0.67) subunits of PKA in platelets from the three groups. As shown in Figure   Figure 1 Representative immunoblots of regulatory type I (RI), type II (RII) and catalytic (C) subunits of cAMP-dependent protein kinase, Rap1 and actin immunoreactivity in platelets from control subjects (CON) and untreated euthymic (E MD), or depressed (D MD) patients with major depressive disorder. Western blot analysis was performed as described in Methods. S and MW indicate standard platelet proteins and apparent molecular weight, respectively. 2, significant differences were found in the levels of the RII subunit of the enzyme (F 2,87 = 17.42; P Ͻ 0.001). Post hoc comparisons showed that unipolar patients during depressive episodes had about 22% and 19% significantly lower immunolabeling of RII subunit than euthymic patients and controls, respectively: depressed vs euthymic patients, P Ͻ 0.001; depressed patients vs control subjects, P Ͻ 0.001. No differences were found when comparing euthymic patients vs controls ( Figure 2) .
As determined by the analysis of variance, the immunolabeling of Rap1 was significantly different among groups (F 2,87 = 16.63; P Ͻ 0.001). Post hoc comparisons showed that depressed patients had about 15% significantly lower (P Ͻ 0.001) immunolabeling of Rap1 when compared to both euthymic patients and healthy subjects (Figure 3 ). No differences were found between euthymic patients and controls (Figure 3) . The immunostaining for the cytoskeletal protein actin (Figure 1 ), used as internal control, was performed in all collected specimens to test whether nonspecific effects could occur in our experimental conditions. The analysis of the immunoblots revealed no statistical difference in the actin immunoreactivity among the three groups (F 2,87 = 1.61; P = 0.20).
Discussion
The current investigation demonstrates that untreated unipolar patients have abnormal levels of the RII subunit of PKA and Rap1. In particular, significantly lower immunolabeling of platelet PKA RII subunit and Rap1 was found in depressed patients when compared with values of both euthymic patients and control subjects. No significant difference in the immunolabeling of PKA subunits and Rap1 were found between euthymic unipolar patients and control subjects, thus suggesting that the observed modifications could be a state related biochemical abnormality of major depressive disorder.
We are aware that great caution is warranted in extrapolating from platelet findings to those that might be found within a subset of neurons in specific brain regions of unipolar patients with major depression. A major caveat in interpreting data from peripheral models is that the blood cells are exposed to a potentially different neurohormonal environment than that of brain tissue. However, viewed from another perspective, the modifications observed in platelets from depressed but not euthymic unipolar patients may be ascribed to the altered levels of ACTH and cortisol, as well as circulating levels of norepinephrine and metabolites reported in some patients with depression. Interestingly, together these findings may contribute to explain the relationship of depression to cardiovascular disease. [24] [25] [26] [27] [28] [29] Recent studies have reported that abnormalities in some components of cAMP signaling in patients with affective disorders were likely treatment-related rather than disease-related. 7, 14, 15 Thus, in order to reduce the possible influence of previous exposure to psychotropic drugs, the design of our study included patients who were free of antidepressants and of all psychotropic medications for at least 6 and 3 months, respectively.
It is unlikely that the reported modifications can be the result of a general alteration of platelet proteins, given that the results of immunostaining for the other PKA subunits as well as for actin, a cytoskeletal protein used as internal control, showed no changes among groups.
Our findings agree with those of early studies reporting reduced cAMP binding activity in depressed patients. 7, 8 In fact, since the R subunit of PKA represents the cAMP receptor, 1-3 the altered cAMP binding activity might be explained by the lower levels of the R subunit herein reported.
Recent data have shown that abnormalities in PKA activity are related to the subtype of depression. 11 Considering that all patients participating in our study Molecular Psychiatry were of melancholic type, it will be interesting to investigate whether the abnormalities herein reported may also be present in other subtypes of depression.
Consonant with the hypotheses of cAMP signaling system dysfunctions in depression, 4, 6, 30 our results may be directly linked to alterations in the levels and function of the G proteins-adenylyl cyclase-cAMP cascade previously reported in patients with major depression. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Alternatively, the observed modifications may reflect adaptive responses to other reported dysfunctions in cell signaling of depressed patients such as Ca 2+ signaling and the phosphoinositides cycle, including protein kinase C. [40] [41] [42] [43] [44] [45] [46] These findings alone or in combination may contribute to explain the reason why PKA and Rap1 are altered in major depression, but the molecular mechanisms by which these modifications occur remain unknown.
While the involvement of PKA in affective disorders seems to be potentially clear, future research is needed to elucidate the role of Rap1. Interestingly, according to recent data Rap1 seems to regulate or be regulated by several signal transduction pathways, including those linked to neurotropic factors, 16 ,47-55 most of which have been found altered in affective disorders. 4, 6, 30, [56] [57] [58] [59] [60] [61] The current data, joined to our previous study, 20 suggest that dysfunctions of the cAMP signaling system are linked to both major depression and bipolar disorder. However, it is worth mentioning that the manner in which PKA and Rap1 are altered in both disorders is somewhat different, thus suggesting that bipolar and unipolar disorders may be associated with distinctive biochemical abnormalities of a common pathway. Although future research is needed to elucidate the actual involvement of cAMP signaling in affective disorders, we feel that the reported abnormalities in PKA and Rap1 may be relevant to explain certain pharmacological and/or clinical features of affective disorders. This latter speculation is supported by a great amount of emerging evidence suggesting that PKA and some of its substrates are implicated in the action of antidepressant medications [4] [5] [6] 56 and also in the regulation of motor and emotive behavior, memory, and stress. 4, [60] [61] [62] [63] [64] [65] In conclusion, unipolar patients during depressive episodes, but not in euthymia, have altered levels of platelet PKA RII subunit and Rap1. These findings support and extend the current thinking about the role of the cAMP-dependent phosphorylation system in the pathophysiology of affective disorders.
